<code id='EB5B0328B5'></code><style id='EB5B0328B5'></style>
    • <acronym id='EB5B0328B5'></acronym>
      <center id='EB5B0328B5'><center id='EB5B0328B5'><tfoot id='EB5B0328B5'></tfoot></center><abbr id='EB5B0328B5'><dir id='EB5B0328B5'><tfoot id='EB5B0328B5'></tfoot><noframes id='EB5B0328B5'>

    • <optgroup id='EB5B0328B5'><strike id='EB5B0328B5'><sup id='EB5B0328B5'></sup></strike><code id='EB5B0328B5'></code></optgroup>
        1. <b id='EB5B0328B5'><label id='EB5B0328B5'><select id='EB5B0328B5'><dt id='EB5B0328B5'><span id='EB5B0328B5'></span></dt></select></label></b><u id='EB5B0328B5'></u>
          <i id='EB5B0328B5'><strike id='EB5B0328B5'><tt id='EB5B0328B5'><pre id='EB5B0328B5'></pre></tt></strike></i>

          Home / Wikipedia / focus

          focus


          focus

          author:Wikipedia    Page View:3
          The New York Stock Exchange's screen displays a logo of Johnson & Johnson — pharma coverage from STAT
          AP/Richard Drew

          Johnson & Johnson said Monday that it would purchase Ambrx Biopharma for nearly $2 billion, picking up a company specializing in targeted chemotherapy treatments — one of the hottest areas of cancer drug development. 

          The deal, disclosed as the biopharma field marked the first day of the annual J.P. Morgan Healthcare Conference, extends a recent spate of pharma acquisitions, contributing to hopes that 2024 could be a better year for the industry. 

          advertisement

          Under the agreement, J&J will pay $28 per share in cash for Ambrx, roughly a 100% premium to the latter’s recent trading price. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In